Von Hippel-Lindau syndrome

Frontiers of Hormone Research

Volumn 41, Issue , 2013, Pages 30-49

  Chou, Angela ^a   Toon, Christopher ^b,c   Pickett, Justine ^b   Gill, Anthony J ^b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

ARTICLE; CLINICAL FEATURE; GENOTYPE PHENOTYPE CORRELATION; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY CYST; MISSENSE MUTATION; MOLECULAR GENETICS; PANCREATIC NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 84877938018     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000345668     Document Type: Article

References (115)

1. Maher ER, et al: von Hippel-Lindau disease: a genetic study. J Med Genet 1991; 28: 443-447.
2. Chen F, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5: 66-75.
3. Maher ER, et al: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77: 1151-1163.
4. Melmon KL, Rosen SW: Lindau's disease. Review of the literature and study of a large kindred. Am J Med 1964; 36: 595-617.
5. Richards FM, et al: Mapping the von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 1993; 2: 879-882.
6. Maher ER, Neumann HP, Richard S: von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19: 617-623.
7. Beroud C, et al: Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 1998; 26: 256-258.
8. Richards FM, et al: Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 1995; 4: 2139-2143.
9. Wu P, et al: Family history of von Hippel-Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. J Hum Genet 2012; 57: 238-243.
10. Crossey PA, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994; 3: 1303-1308.
11. Franke G, et al: Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat 2009; 30: 776-786.
12. McNeill A, et al: Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet A 2009; 149A:2147-2151.
13. Richards FM, et al: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996; 5: 639-644.
14. Kaelin WG Jr: The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005; 338: 627-638.
15. Kibel A, et al: Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995; 269: 1444-1446.
16. Kamura T, et al: The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999; 13: 2928-2933.
17. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999; 284: 455-461.
18. Lisztwan J, et al: The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13: 1822-1833.
19. Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein: O 2 sensing and cancer. Nat Rev Cancer 2008; 8: 865-873.
20. Yang H, et al: pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007; 28: 15-27.
21. Chitalia VC, et al: Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 2008; 10: 1208-1216.
22. Nakamura E, et al: Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 2006; 168: 574-584.
23. Richard S: von Hippel-Lindau disease: recent advances and therapeutic perspectives. Expert Rev Anticancer Ther 2003; 3: 215-233.
24. Niemela M, et al: Hemangioblastomas of the retina: impact of von Hippel-Lindau disease. Invest Ophthalmol Vis Sci 2000; 41: 1909-1915.
25. Neumann HP, et al: Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 1998; 160: 1248-1254.
26. Ong KR, et al: Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007; 28: 143-149.
27. Maddock IR, et al: A genetic register for von Hippel-Lindau disease. J Med Genet 1996; 33: 120-127.
28. Manski TJ, et al: Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997; 277: 1461-1466.
29. Libutti SK, et al: Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 1998; 124: 1153-1159.
30. Dollfus H, et al: Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43: 3067-3074.
31. Aiello LP, et al: Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002; 109: 1745-1751.
32. Girmens JF, et al: Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003; 136: 194-196.
33. Wanebo JE, et al: The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98: 82-94.
34. Wind JJ, Lonser RR: Management of von Hippel-Lindau disease-associated CNS lesions. Expert Rev Neurother 2011; 11: 1433-1441.
35. Ammerman JM, et al: Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 2006; 105: 248-255.
36. Jagannathan J, et al: Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2008; 108: 210-222.
37. Mehta GU, et al: Functional outcome after resection of spinal cord hemangioblastomas associated with von Hippel-Lindau disease. J Neurosurg Spine 2010; 12: 233-242.
38. Wind JJ, et al: Long-term outcome after resection of brainstem hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 2011; 114: 1312-1318.
39. Asthagiri AR, et al: Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro-Oncology 2010; 12: 80-86.
40. Lonser RR, et al: Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol 2005; 58: 392-399.
41. Chan CC, et al: VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 1999; 117: 625-630.
42. Vortmeyer AO, et al: von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997; 28: 540-543.
43. Hussein MR: Central nervous system capillary haemangioblastoma: the pathologist's viewpoint. Int J Exp Pathol 2007; 88: 311-324.
44. Hasselblatt M, et al: Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases. Neuropathol Appl Neurobiol 2005; 31: 618-622.
45. Polydorides AD, Rosenblum MK, Edgar MA: Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med 2007; 131: 641-645.
46. Carney EM, et al: PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol 2011; 35: 262-267.
47. Kennedy M, et al: Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 2007; 109: 2679-2687.
48. Vortmeyer AO, et al: Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 2004; 55: 721-728.
49. Shively SB, et al: Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol 2011; 24: 1023-1030.
50. Jilg CA, et al: Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up. Fam Cancer 2012.
51. Johnson A, et al: Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008; 180: 89-93.
52. Steinbach F, Novick AC, Shoskes D: Renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Urology 1994; 44: 760-763.
53. Poston CD, et al: Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 1995; 153: 22-26.
54. Walther MM, et al: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995; 154: 2010-2014; discussion 2014-2015.
55. Lutz MS, Burk RD: Primary cilium formation requires von Hippel-Lindau gene function in renalderived cells. Cancer Res 2006; 66: 6903-6907.
56. Thoma CR, Frew IJ, Krek W: The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle 2007; 6: 1809-1813.
57. Esteban MA, et al: Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. J Am Soc Nephrol 2006; 17: 1801-1806.
58. Plotnikova OV, Pugacheva EN, Golemis EA: Primary cilia and the cell cycle. Methods Cell Biol 2009; 94: 137-160.
59. Thoma CR, et al: pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol 2007; 9: 588-595.
60. Montani M, et al: VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 2010; 34: 806-815.
61. Sourbier C, et al: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007; 67: 11668-11676.
62. Morais C, et al: The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011; 43: 1537-1549.
63. Hes FJ, Hoppener JW, Lips CJ: Clinical review 155: Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 2003; 88: 969-974.
64. Walther MM, et al: Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162: 659-664.
65. Welander J, Soderkvist P, Gimm O: Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:R253-R276.
66. Koch CA, et al: Pheochromocytoma in von hippellindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 2002; 13: 17-27.
67. Lee CM, et al: VHL type 2B gene mutation moderates HIF dosage in vitro and in vivo . Oncogene 2009; 28: 1694-1705.
68. Girelli R, et al: Pancreatic cystic manifestations in von Hippel-Lindau disease. Int J Pancreatol 1997; 22: 101-109.
69. Agrawal D, et al: Prevalence and clinical significance of pancreatic cysts associated with cysts in other organs. Dig Liver Dis 2011; 43: 797-801.
70. Kanno A, et al: Serous cystic neoplasms of the whole pancreas in a patient with von Hippel-Lindau disease. Intern Med 2011; 50: 1293-1298.
71. Scolari F, et al: von Hippel-Lindau syndrome presenting as pancreatic cysts. Contrib Nephrol. Basel, Karger, 2001, vol 136, pp 325-330.
72. Libutti SK, et al: Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000; 128: 1022-102.
73. Corcos O, et al: Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 2008; 37: 85-93.
74. Hoang MP, Hruban RH, Albores-Saavedra J: Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 2001; 25: 602-609.
75. Perigny M, et al: Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 2009; 33: 739-748.
76. Lubensky IA, et al: Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 1998; 153: 223-231.
77. Blandamura S, et al: Three cases of pancreatic serous cystadenoma and endocrine tumour. J Clin Pathol 2007; 60: 278-282.
78. Blansfield JA, et al: Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142: 814-818.
79. Chung DC, et al: A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997; 100: 404-410.
80. Speisky D, et al: Molecular profiling of pancreatic neuroendocrine tumors in sporadic and von Hippel-Lindau patients. Clin Cancer Res 2012; 18: 2838-2849.
81. Heffner DK: Low-grade adenocarcinoma of probable endolymphatic sac origin. A clinicopathologic study of 20 cases. Cancer 1989; 64: 2292-2302.
82. Joy HM, et al: Radiological considerations in the diagnosis of an endolymphatic sac tumour. Clin Radiol 2002; 57: 652-654.
83. Lonser RR, et al: The vestibular aqueduct: site of origin of endolymphatic sac tumors. J Neurosurg 2008; 108: 751-756.
84. Michaels L: Origin of endolymphatic sac tumor. Head Neck Pathol 2007; 1: 104-111.
85. Glasker S, et al: Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 2005; 65: 10847-10853.
86. Bell D, et al: Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience. Ann Diagn Pathol 2011; 15: 117-123.
87. Kawahara N, et al: VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Neurology 1999; 53: 208-210.
88. Jensen RL, et al: Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. J Neurosurg 2004; 100: 488-497.
89. Vortmeyer AO, et al: Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 2000; 60: 5963-5965.
90. Nogales FF, et al: An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: four associated with von Hippel-Lindau disease and one aggressive sporadic type. Histopathology 2012; 60: 748-757.
91. Glasker S, et al: Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. J Pathol 2006; 210: 32-41.
92. Aydin H, et al: Clear cell papillary cyst adenoma of the epididymis and mesosalpinx: immunohistochemical differentiation from metastatic clear cell renal cell carcinoma. Am J Surg Pathol 2005; 29: 520-523.
93. Odrzywolski KJ, Mukhopadhyay S: Papillary cystadenoma of the epididymis. Arch Pathol Lab Med 2010; 134: 630-633.
94. Browning L, Parker A: Bilateral adrenal haemangioblastoma in a patient with von Hippel-Lindau disease. Pathology 2008; 40: 429-431.
95. Rojiani AM, et al: Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. Am J Surg Pathol 1991; 15: 81-86.
96. Sinkre PA, et al: Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol 2001; 25: 1334-1339.
97. Karasawa Y, et al: Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel-Lindau disease type 2A. Intern Med 2001; 40: 38-43.
98. Wagner M, et al: Lipid cell tumors in two women with von Hippel-Lindau syndrome. Obstet Gynecol 2010; 116(suppl 2):535-539.
99. Xu DS, et al: A von Hippel-Lindau disease-associated microcystic adenoma of the ethmoid sinus: case report. Neurosurgery 2011; 69:E1017-E1021; discussion E1021-E1022.
100. Klein J, et al: Multifocal microcysts and papillary cystadenoma of the lung in von Hippel-Lindau disease. Am J Surg Pathol 2007; 31: 1292-1296.
101. Ng HK, Tse JY, Poon WS: Cerebellar astrocytoma associated with von Hippel-Lindau disease: case report with molecular findings. Br J Neurosurg 1999; 13: 504-507.
102. Marinozzi A, et al: Chondrosarcoma of the iliac wing in von Hippel-Lindau disease. J Exp Clin Cancer Res 2007; 26: 599-601.
103. Lonser RR, et al: von Hippel-Lindau disease. Lancet 2003; 361(9374):2059-2067.
104. Maher ER: von Hippel-Lindau disease. Curr Mol Med 2004; 4: 833-842.
105. Arjumand W, Sultana S: Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012; 33: 9-16.
106. Motzer RJ, et al: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-1887.
107. Escudier B, et al: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318.
108. Escudier B: Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010; 10: 305-317.
109. Hudes G, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
110. Bajetta E, Guadalupi V, Procopio G: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2009; 27: 319-320; author reply 320.
111. Kulke MH, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
112. Ali T, Kandil D, Piperdi B: Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with von Hippel-Lindau syndrome (VHL). Pancreas 2012; 41: 492-493.
113. Jimenez C, et al: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009; 94: 386-391.
114. Kim BY, Jonasch E, McCutcheon IE: Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: Case report. Target Oncol 2012.
115. Jones DT, Harris AL: Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opin Ther Targets 2012.